The retrospective analysis reviews functional longevity across decades of Utah array implants, providing a historical benchmark for next-generation chronic device design.
The study reports methods for evoking finer-grained phosphene patterns via high-density surface arrays, offering a path toward higher-resolution visual information for blind patients.
The closed-loop protocol dynamically adjusted stimulation based on real-time neural signals, yielding significantly greater symptom improvement versus open-loop controls.
The system uses external RF power delivery for fully wireless recording, removing the mobility constraints of wired connections; validated in animal models.
The study compared glial scarring around flexible versus rigid electrodes, finding significantly milder tissue response in the flexible group.
Researchers tracked signal quality of high-density arrays implanted over two years, finding roughly 70% of channels still yielding usable signal.
The study integrates large language models into post-decoding processing, further reducing word error rate toward conversational usability.
The trial evaluates the companys neural interface system in assisting paralyzed patients with daily tasks; the new site is expected to accelerate enrollment.
Following the 30-day implantation clearance, the company announced the launch of a pivotal-stage study targeting motor function restoration.
The report discloses electrode channel attrition among early participants; most channels remained stable while a minority showed gradual signal degradation.
Data showed no device-related serious adverse events across participants, with functional usage metrics improving further from the early feasibility stage.
The Breakthrough Device designation is expected to accelerate FDA review of the next-generation recording array intended for multiple indications.
The round will fund Synchrons pivotal COMMAND trial and commercialization efforts, among the largest single rounds in the BCI sector to date.
Neuralink disclosed expanded enrollment in its PRIME early feasibility study, with early participants sustaining over a year of stable device operation.
The device was previously cleared only for intraoperative use up to 30 minutes. Extending to 30 days opens the door to longer-duration clinical studies.